Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual General Meeting of Shareholders held by ADC Therapeutics SA on June 1, 2026. The filing details the voting outcomes for twelve proposals, including the approval of financial statements for the year ended December 31, 2025, director elections, and amendments to the company's articles of association.
Key Financial Metrics
The filing confirms that the company reported a net loss for the year ended December 31, 2025, which shareholders approved to be carried forward. Specific revenue, profit, cash flow, margin, debt, or liquidity figures are not provided in this document; investors should refer to the previously filed definitive proxy statement and annual financial statements for detailed metrics.
Material Changes and Voting Results
- Financial Statements: Shareholders approved the management report and consolidated financial statements for 2025 with 79,705,454 votes in favor.
- Capital Structure Amendments: Shareholders approved significant amendments to the articles of association to increase the company's capital range and conditional share capital for employee participation, financing, and acquisitions.
- Equity Plan: An amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan was approved.
- Compensation Caps: Shareholders approved binding caps on compensation: $2.5 million for the Board of Directors, $2.6 million for fixed executive committee compensation, and $5.5 million for variable executive committee compensation.
- Contested Votes: Proposals regarding the Board compensation cap (Proposal 9a), the Equity Incentive Plan increase (Proposal 11), and the capital range amendments (Proposal 12a-d) received significant "Against" votes, ranging from approximately 16.9 million to 18.9 million votes against.
Guidance, Outlook, and Risks
This filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the voting results. The approval of increased conditional share capital suggests management is preparing for potential future financing or acquisition activities. The significant opposition to the Board compensation cap and equity plan expansion may indicate shareholder sentiment regarding capital allocation and executive pay.
Investor Verification Checklist
- Verify the specific financial performance details (revenue, R&D spend, cash position) in the 2025 Annual Report referenced in Proposal 1.
- Review the definitive proxy statement for the rationale behind the contested compensation caps and equity plan expansion.
- Monitor the company's capital raise activities given the newly approved increases in conditional share capital.
- Assess the implications of the significant "Against" votes on future shareholder engagement and governance policies.